Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. It is also developing a preclinical program focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. It is also developing a preclinical program focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.